We came across a bullish thesis on Zoetis Inc. on Summit Stocks’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.'s share was trading at $142.26 as of October 13th. ZTS’s trailing and forward P/E were 25.21 and 21.69 respectively according to Yahoo Finance. Photo by Karlo Tottoc on Unsplash Zoetis is the global leader in animal pharmaceuticals, recognized for its high-quality, durable business model and consistent outperformance in the animal health sector. The industr ...

With a market cap of $64.3 billion, Zoetis Inc. (ZTS) is a global leader in animal health, specializing in the discovery, development, and commercialization of medicines, vaccines, diagnostics, and precision animal health products for both livestock and companion animals. The company’s diversified portfolio spans multiple species and product categories, catering to veterinarians, livestock producers, and pet owners worldwide. The Parsippany, New Jersey-based company is slated to announce its fiscal Q3 202 ...

Kristin Peck runs a pioneering animal-health company—but at the heart of her leadership success is a focus on people. She shares how she builds a culture that excels. Recorded on June 11, 2025. #Business #Interview #WSJ ...

Zoetis Inc. (NYSE:ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging. With UBS recently lowering its price targets, it adds further weight to the view that Zoetis could stay stuck in a slump through June 2026. Zoetis and Its Weak Guna TriadsIn the Adhishthana framework, the behavior of Phase 18 is largely determined by Phases 14, 15, and 16, collectively known as the Guna Triads. These ph ...

Core Insights - Zoetis (ZTS) has a strong history of beating earnings estimates and is well-positioned for future earnings growth [1][5] - The company has surpassed earnings estimates by an average of 7.18% over the last two quarters [1][5] - The upcoming earnings report is expected on November 4, 2025 [8] Earnings Performance - For the last reported quarter, Zoetis achieved earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 per share by 8.64% [2] - In the previous quarter, the company reported earnings of $1.48 per share against an expectation of $1.4 per share, resulting in a surprise of 5.71% [2] Earnings Estimates and Predictions - Estimates for Zoetis have been trending higher, supported by its history of earnings surprises [5] - The company currently has an Earnings ESP of +0.41%, indicating a positive outlook from analysts regarding its earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat [8][6]

Key Takeaways Zoetis gained CVMP support for Lenivia, a monoclonal antibody for canine OA pain relief.Lenivia offers up to 3 months of pain relief with one jab and was well-tolerated in clinical studies.Lenivia will complement Librela, giving vets and owners both monthly and quarterly OA pain therapy options.Zoetis (ZTS) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, Le ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection. ...

Always on the hunt for undervalued, promising stocks with a focus on risk and reward. Limited risks and decent to high upside by knowing what one's owning. I strongly believe that the best investment ideas are often the simplest. If contrarian, the better.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not ...

Core Insights - The article discusses the author's background in analytics and accounting, highlighting over 10 years of experience in the investment arena, starting as an analyst and progressing to a management role [1]. Group 1 - The author holds a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1]. - The author has a personal interest in dividend investing and aims to share insights with the Seeking Alpha community [1]. Group 2 - The author has disclosed a beneficial long position in several companies, including ODFL, ZTS, MSCI, DPZ, INTU, ACN, WST, and SBAC, through various financial instruments [2]. - The article expresses the author's personal opinions and does not involve compensation from any mentioned companies [2].

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Zoetis Inc. is one of them. Zoetis Inc. (NYSE:ZTS), a global leader in animal health, reported solid second-quarter 2025 results with revenue rising 4% year-over-year to $2.5 billion and net income up 15% to $718 million. Growth was driven by an 8% increase in companion animal product sales, led by flagship products such as Simparica Trio for parasite prevention and pain and dermatology treatments, including Rela Sol ...